• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Blogs » BioWorld MedTech Perspectives » The Good, the Bad and the Ugly: Third-party coverage requests

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Cardiovascular / CMS / Medicare

The Good, the Bad and the Ugly: Third-party coverage requests

Sep. 30, 2011
By Mark McCarty

As a member of the trade press, I get a kick out of how routinely some people in the mainstream media and the population at large routinely assume that device makers are driven by greed and that doctors are morally flawless creatures who spend all their spare time pondering the public weal and woe, continuously devising ways to ensure their passage through the Pearly Gates with constant acts of selflessness.

The Realm of the Coin

And then I see the parties weighing in on the question of Medicare coverage for the Sapien aortic valve made by Edwards Lifesciences (Irvine, California), and I say to myself, “oh sure. Selfless!”

On the one hand, setting up the registries that will be charged with tracking the device's performance in the post-market world won't be cheap. On the other, the kindly doctor who will see you now isn't doing it for free, I promise you that. I love how the Sept. 22 letter from the Society of Thoracic Surgeons (Chicago) and the American College of Cardiology (Washington) bleats about the fact that industry-developed registries are “a major expense to industry and creates potential for conflict of interest.”

Well, if it would cost device makers to set up a registry on their own, who's going to finance the registry set up by STS, ACC and their good pals at the Society for Cardiac Angiography and Interventions (Washington)? Maybe these doctor groups will set up a booth in front of Wal-Mart, but somehow I get the feeling device makers will still be on the hook, and the notion that these doctor groups won't make a blessed dime just doesn't smell right at all. So much for your conflict of interest, something for which docs are notorious.

As if that weren't enough to raise the hair on the back of your neck, add the restrictions to usage of the device proposed by the doctor groups, not to mention the cast from the Broadway production of Hair that has to be in the OR for this procedure. According to ACC, this includes (but might not be limited to) primary cardiologists, cardiac surgeons, interventional cardiologists, echocardiographers and imaging specialists, and heart failure specialists.

The only remaining questions is this: “Has the janitor scrubbed, and how much can we bill for his time?”

There are a couple of cliches that address this kind of thing, including “too many chefs and not enough sous chefs.” Pick whichever you like, but there needn't be any hissy fits involving a miffed specialist snapping off a glove and hurling it at a so-called colleague for this to be a study in overkill. Seriously, what could the primary cardiologist or heart failure specialist possibly have to say beyond, “wow, nifty move with that catheter!”?

Frankly, this whole tale tells you a lot more about homo sapiens than about the Sapien. As the television ad for automobile tires used to say, “tires ain't pretty!”

Neither is human nature.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock

    BioWorld
    Ligachem Biosciences Inc. signed two license agreements with Novarock Biotherapeutics Inc., a subsidiary of CSPC Pharmaceutical Group Ltd., to bring in two of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe